Daiichi Sankyo gets Japenese nod for Tarlige tablets to treat neuropathic pain
Tokyo: Daiichi Sankyo Company, Limited has announced that the company has obtained approval in Japan to change the indication of the analgesic "Tarlige Tablets" (mirogabalin besilate) from "peripheral neuropathic pain" to "neuropathic pain."
Neuropathic pain is pain caused by lesions or diseases of the somatosensory nervous system and is classified into peripheral neuropathic pain and central neuropathic pain (CNP), according to the anatomical location of the nerve damage site that causes the pain. CNP is pain that arises from central nerve injury or impairment such as spinal cord injury and central post-stroke pain.
In May 2021, Daiichi Sankyo submitted a supplemental new drug application (sNDA) for Tarlige Tablets based on results from a phase 3 trial in patients with CNP.
"By delivering a new therapeutic option for CNP, Daiichi Sankyo hopes to contribute to healthcare of patients," the release stated.
Read also: Sun Pharma to acquire Daiichi's 11.28 percent stake in Zenotech
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.